trial

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

NCTId NCT05245539
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 151 (actual)
Sponsored by Cerevel Therapeutics, LLC
Primary completion 2022-10-19
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
151 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2022-01-24
Primary completion
2022-10-19
Eligibility
ALL · 30 Years · 60 Years

Interventions & indications

Drugs
Emraclidine

Sponsors

Cerevel Therapeutics, LLCLead Sponsor

Investigators

1
Erica Koenig, PhDStudy Director

Sites

10 total
Bentonville, United StatesLittle Rock, United StatesLong Beach, United StatesMiami, United StatesChicago, United StatesLincolnwood, United StatesMarlton, United StatesNorth Canton, United StatesAustin, United StatesRichardson, United States

Facts & assertions

4 sourced
Enrollment
151
Phase
PHASE1
Primary Completion Date
2022-10-19
Status
COMPLETED
relationships
The graph out of here
drug
Emraclidine
drug
lead_sponsor
Cerevel Therapeutics, LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication
Blood Pressure
indication
investigator
Erica Koenig, PhD
person